1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY (USD BILLION)
6.1. Next Generation Sequencing
6.2. Polymerase Chain Reaction
6.3. In Situ Hybridization
6.4. Immunohistochemistry
7. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY APPLICATIONS (USD BILLION)
7.1. Therapeutic Monitoring
7.2. Patient Stratification
7.3. Predictive Testing
7.4. Disease Diagnosis
8. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER (USD BILLION)
8.1. Hospitals
8.2. Diagnostic Laboratories
8.3. Research Institutions
8.4. Pharmaceutical Companies
9. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TEST TYPE (USD BILLION)
9.1. Genetic Tests
9.2. Protein Biomarker Tests
9.3. MicroRNA Tests
9.4. Pathological Analysis
10. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Companion Diagnostics for Oncology Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Companion Diagnostics for Oncology Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Pfizer
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Merck and Co
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Myriad Genetics
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Thermo Fisher Scientific
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. BioMérieux
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Exact Sciences
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12
6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Roche
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. AbbVie
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Illumina
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Guardant Health
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Novartis
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Agilent Technologies
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Horizon Discovery
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Qiagen
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 3. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 4. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 5. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 6. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 7. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 8. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 9. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 10. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 11. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 12. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 13. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 14. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 15. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 16. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 17. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 18. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 19. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 20. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 21. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 22. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 23. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 24. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 25. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 26. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 27. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 28. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 29. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 30. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 31. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 32. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 33. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 34. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 35. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 36. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 37. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 38. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 39. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 40. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 41. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 42. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 43. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 44. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 45. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2035 (USD BILLIONS)
TABLE 46. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 47. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD BILLIONS)
TABLE 48. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATIONS, 2019-2035 (USD BILLIONS)
TABLE 49. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE E
